Dyspareunia Treatment Market Size and Trends

The dyspareunia treatment market is estimated to be valued at USD 754.1 Mn in 2024 and is expected to reach USD 1,035.4 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.6% from 2024 to 2031.

Dyspareunia Treatment Market Key Factors

To learn more about this report, request sample copy

The dyspareunia treatment market has been witnessing positive trends with growing focus on developing new and more effective therapeutics. While topical drugs continue to hold the largest share currently, the segments of oral therapies and medical devices are expected to offer lucrative opportunities with ongoing research on drug delivery methods and minimally invasive procedures. Successful new product launches addressing the unmet needs can further accelerate market expansion over the forecast period.

Increasing Awareness and Openness about Sexual Health Issues

Growing societal acceptance and open discussions around female sexuality and sexual health issues have significantly boosted awareness about dyspareunia in recent times. Not too long ago, female sexual pains and dysfunctions were brushed under the carpet due to stigma and conservatism. However, with more women coming forward to share their experiences, dyspareunia is no longer a hidden problem. Several influencers on social media who are sexual wellness advocates have ramped up conversations around sexuality. Their efforts have played a big role in assuaging misconceptions and guilt surrounding such issues. Women have started understanding that they are not alone in experiencing genital pain during or after intercourse and it is not a result of physical abnormality or their moral weakness. The taboo around sexual health issues is now slowly dissipating. More women feel empowered to seek help rather than tolerate pain in silence. Several non-profit organizations are active in creating public awareness campaigns and seminars to educate people about sexual wellness. The medical community too has become more responsive and sensitive while addressing such problems. Gynecologists and general physicians nowadays are able to carefully diagnose and reassure women rather than dismiss their concerns. Overall, the paradigm shift towards a healthier and open treatment of sexuality on both social and medical fronts has motivated dyspareunia sufferers to explore treatment options. The stigma lift has enabled earlier diagnosis and management of the condition.

Increasing Product Launches by Key Market Players

Increasing adoption of organic growth strategies, such as product launches, by key market players for the treatment of dyspareunia are expected to drive the market growth over the forecast period. For instance, in February 2022, Duchesnay Inc., a global pharmaceutical company, announced that it had launched Osphena (ospemifene tablets), a Selective Estrogen Receptor Modulator (SERM) in Canada for the treatment of vaginal dryness and dyspareunia. Osphena has been shown in phase II and III clinical studies to treat moderate to severe dyspareunia (painful intercourse) and/or vaginal dryness in postmenopausal women, which are symptoms of vulvar and vaginal atrophy (VVA), a component of genitourinary syndrome of menopause (GSM).